Author Archives: Samantha Truex

SPAC downpour continues
July 9, 2021

By Sam Truex, Venture Partner at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. Holy cow, have we seen the rain lately – both downpours outside and a downpour of SPAC activity. In October 2020, Bruce

Leave a comment

Ode to Scientists
April 1, 2021

By Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC In the fall of 2019, I wrote a blog called Ode to Patients.  As stresses from many directions have mounted over the past

Leave a comment

Leave a Ladder Down, Part Deux
July 20, 2020

By Samantha Truex, CEO of QuenchBio, as part of the From The Trenches feature of LifeSciVC I have been privileged to read and write for this LifeSciVC blog for a handful of years now.  One of my favorite editions is

Leave a comment

Confessions Of A Planner
April 3, 2020

This blog was written by Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC.  I am a planner.  I like to plan most things well in advance; in fact, maybe too far in

Leave a comment

Ode to Patients 
October 15, 2019

This blog was written by Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC. Due to meetings in London on a Friday and in Dortmund on the following Monday, I spent the weekend

Leave a comment

Tips for Industry-Academia Collaboration
July 24, 2019

This blog was written by Samantha Truex, Atlas EIR and CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC. Some of the most promising and innovative research underlying biotech start-ups arises in research institutions.  It

Leave a comment

Maybe It’s Innate
April 30, 2019

This blog was written by Samantha Truex, Atlas EIR and CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC. Recently I read the article What’s Wrong With Me? that I saw re-posted on Twitter.  It’s

Leave a comment

All A-Board
February 14, 2019

This blog is written by Samantha Truex, Atlas EIR and CEO of a stealth-stage biotech, as part of the From The Trenches feature of LifeSciVC. In a 2014 analysis  of biotech boards and a reprise analysis in 2016, Bruce Booth

Leave a comment

How’s My Baby?
October 24, 2018

This blog was written by Samantha Truex, CEO of Quench Bio and Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC. In early September, I saw my two teenagers off to new destinations where they will live

Leave a comment

Just a Little Patience: In-licensing from Biopharma
March 20, 2018

This blog was written by Samantha Truex, an Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC. People who know me well will agree that patience is not one of my personal virtues.  That said, I recognize

Leave a comment

To IPO or Not To IPO
October 25, 2017

This blog was written by Sam Truex, former CBO of Padlock and Synlogics, and current Atlas EIR, as part of the From the Trenches feature of LifeSciVC. Funding for biotech companies has been abundant this year. As covered the first

2 Comments

Option Or Warrant: Alternative Structures For A Future Acquisition
November 15, 2016

This blog was written by Samantha Truex, former CBO of Padlock Therapeutics and Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC. The search for creative deal structures that strike a “win-win” balance is a noble one.

2 Comments

Beyond Biotech M&A: What Comes Thereafter
September 22, 2016

This post was written by Samantha Truex, former CBO of Padlock Therapeutics, as part of the From The Trenches feature of LifeSciVC. Biotech M&A is all the rage these days. Allergan has acquired four small companies in the past couple

Leave a comment

Biotech BD Transactions: The Soft Stuff
June 27, 2016

This blog was written by Samantha Truex, former CBO of Padlock Therapeutics, as part of the From The Trenches feature of LifeSciVC. I grew up in a setting where “continuous improvement” and “total quality management” were household terms, as unusual

1 Comment